BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
World's top technology exhibition CES 2021
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

Daewoong to stage clinical trials of COVID-19 treatment using stem cells

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : July 6, 2020, 14:51 | Updated : July 6, 2020, 14:51
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Daewoong Pharmaceutical]


SEOUL -- Daewoong Pharmaceutical, a major bioengineering company in South Korea, will carry out the first phase of clinical trials in Indonesia for COVID-19 respiratory symptom treatment using mesenchymal stem cells after drug efficacy tests using animal models have identified anti-inflammatory and antiviral effects.

If the stability of DWP710 is confirmed in phase 1 clinical trials, Daewoong will go to the next stage of testing in South Korea within this year. Daewoong's joint venture in Indonesia is in charge of phase 1 testing. "We will speed up development so that the drug can be commercialized as quickly as possible," said Daewoong CEO Jeon Seung-ho.

Mesenchymal stem cells (MSCs) are multipotent stromal cells that can differentiate into a variety of cell types, including bone cells, cartilage cells, muscle cells and fat cells which give rise to marrow adipose tissue. MSCs have a great capacity for self-renewal while maintaining their multipotency.

In the testing of animals with acute respiratory disease syndrome, Daewoong said that DWP710 increased the survival rate by more than 30 percent, compared to a comparison group, while lung tissues damaged by inflammatory reactions recovered close to normal.

Daewoong has introduced a cell banking system. Daewoong's stem cells can be used immediately for patients because they can be frozen and stored in hospitals. The company claimed to have achieved progress in the initial animal testing of niclosamide, a tapeworm treatment medicine selected as a candidate for COVID-19 antibody treatment.

Institut Pasteur Korea, an infectious disease-focused research institute, has embarked on a co-research mission with a subsidiary of Daewoong, to test the efficacy of niclosamide (DWRX2003), which basically starves tapeworms to death. The medication is currently being researched for its effectiveness against various types of cancer.

 

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Preliminary approval to finance production of Daewoongs tapeworm treatment medicine  .
    Preliminary approval to finance production of Daewoong's tap…
  • .Daewoong allowed to test efficacy of tapeworm treatment medicine in Philippines.
    Daewoong allowed to test efficacy of tapeworm treatment medi…
  • .Daewoong allowed to conduct third-stage combination therapy with diabetes drug candidate.
    Daewoong allowed to conduct third-stage combination therapy …
  • .Daewoong shares up in domestic market after 21-month ban by U.S. trade panel  .
    Daewoong shares up in domestic market after 21-month ban by …
  • .Daewoong seeks Philippine approval to test tapeworm treatment medicine .
    Daewoong seeks Philippine approval to test tapeworm treatmen…

Real Time Photo News

  • .Singer IU drops teaser image for upcoming full album.

    Singer IU drops teaser image for upcoming full album

  • .Cube Entertainment partners with web comics company to create online video content.

    Cube Entertainment partners with web comics company to create online video content

  • .Sci-fi film starring Song Joong-ki to be reelased on Netflix in February.

    Sci-fi film starring Song Joong-ki to be reelased on Netflix in February

  • .Actor Kim Soo-hyun to star in S. Korean remake of British TV drama series Criminal Justice.

    Actor Kim Soo-hyun to star in S. Korean remake of British TV drama series 'Criminal Justice'

  • .CJ ENM partners with NCSoft to roll out new digital content for global market.

    CJ ENM partners with NCSoft to roll out new digital content for global market

Latest News

more+

  • Singer IU drops teaser image for upcoming full album
  • Hyundai to complete construction of fuel cell production plant in China in 2022
  • Seoul builds solar power plant on idle land near urban expressway
  • Samsung showcases new Galaxy S21 smartphone models
  • Southern city launches joint research project to develop heavy-duty flying taxi drone
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view